Introduction
============

Diarrhea remains one of the top seven diseases that threaten the lives of children under 5 years old in developing countries. Based on the course of disease, diarrhea can be classified as acute or persistent. Persistent diarrhea, also known as chronic diarrhea, refers to diarrhea persisting for more than 2 weeks.^([@B1])^ Since the beginning of this century, our understanding of the pathogenesis of diarrhea has increased significantly, and treatments for this disease have greatly improved. However, in 2008, diarrheal disease accounted for 1,336 million of the estimated 8,795 million deaths (15%) in children younger than 5 years of age around the world.^([@B2])^ Persistent diarrhea tends to cause malnutrition and growth retardation because the children are trapped in a vicious cycle of "diarrhea-malnutrition-diarrhea" and correspondingly suffer severe health consequences. These consequences impose heavy economic and social burdens on society and families. Hence, a crucial clinical task is improving the malnutrition status of children with persistent diarrhea and decreasing their disease duration.

Vitamin A deficiency (VAD) is one of the three global micronutrient deficiency diseases reported by UNICEF and WHO and is also a leading risk factor for severe infective diseases and death risk in children. Moderate VAD is endemic in China. Our group conducted a preliminary population survey. In 2008, we reported that the incidence of marginal VAD among pre-schoolers in a Chongqing suburb was approximately 30%; however, the rate was higher in rural and poor mountainous areas.^([@B3])^ Qiu *et al.*^([@B4])^ reported that the rate of VA deficiency in children with diarrhea was 2.37-fold greater than that in normal children. Furthermore, increased episodes of diarrhea were correlated with higher VA deficiencies. A survey in India indicated that VA deficiency is an independent risk factor for persistent diarrhea.^([@B5])^ In light of these findings, we investigated whether vitamin A supplementation could ameliorate the malnutrition status of children with persistent diarrhea and improve treatment outcomes. In this study, children with persistent diarrhea were administered with VA auxiliary treatment, with routine Zn intervention as a positive control. Improvements in the nutritional status of children with persistent diarrhea were monitored, and treatment outcomes were evaluated.

Study Subjects and Methods
==========================

Study subjects
--------------

Paediatric patients with persistent diarrhea admitted to the Department of Gastroenterology, Children's Hospital of Chongqing Medical University between April 2013 and February 2014 were recruited in this study. All study subjects were children that had suffered from diarrhea for over 14 days who met the diagnostic criteria for persistent diarrhea.^([@B6])^ The patients had no severe complications of the heart, liver, kidney or hematopoietic systems and were HIV negative. Using a computer-generated random number table, in which each number corresponded to a study serial number assigned to each paediatric patient, the children were randomly allocated into four groups: VA supplementation group (group A), Zn supplementation group (group B), VA + Zn supplementation group (group C) and no supplementation group (group D). Informed consent was obtained from each patient's guardian. This study was approved by the Clinical Ethics Committee of the Children's Hospital of Chongqing Medical University (approval number 008/2013).

Sample size calculation
-----------------------

We estimated that after VA intervention, the minimal value of the Hb increment, δ, was 5 g/L (5 g/L was the observed value in our previous study) and that the standard errors for the group were the following: s = 5 g/L, α = 0.05, and β = 0.01. Using the following equation, we estimated the follow-up loss rate to be 20%; The number of each group was calculated as follows: *n* = \[(Uα + Uβ) × s/δ\]^2^ = \[(1.645 + 1.282) × 10/5\]^2^ = 34(individuals). Thus, the total number of this study was N = *n* ÷ (1 -- 20%) × 4 = 34 ÷ (1 -- 20%) × 4 = 160 (children).

One hundred sixty paediatric patients with persistent diarrhea were randomly assigned to one of the four intervention groups: group A (daily supplementation of 1,500 IU VA for 14 days); group B (daily Zn supplementation for 14 days); group C (daily supplementation with both VA and Zn for 14 days); group D (no supplementation).

Study protocol
--------------

In addition to their routine treatment, the study subjects were also treated with daily supplementation of 1,500 IU VA and/or daily supplementation of Zn (10 mg/day for children \<6 months old and 20 mg/day for children ≥6 months old) for 14 days. During the children's hospitalisation, dedicated nurses were responsible for providing them with medications. The stool and disease conditions of each patient were recorded by a specialised resident. If the intervention course was less than 14 days at the time of discharge, the mother or another guardian of the child was responsible for the remaining period of drug administration, which was monitored by a nurse via telephone follow-ups to ensure that the full 14-day course of VA and/or Zn supplementation was fulfilled. On day 15, when the child returned for outpatient follow-up, his/her mother or guardian was questioned by a specialised physician with respect to the child's stool and other information.

Data collection
---------------

Upon admission, the background information (gender, age in months) and clinical manifestations (stool frequency, properties and systemic symptoms) of each child with persistent diarrhea were documented in detail. Prior to intervention, venous blood was drawn to examine serum biochemical parameters, including levels of VA, Zn, iron, haemoglobin and albumin. In addition, stool was collected for faecal smear tests. After 14 days of intervention, the serum VA level and haemoglobin levels were re-examined. All blood specimens were analysed in the clinical laboratory at our hospital (ISO 15189 approval, laboratory certification CNAS MT0038).

Diagnostic criteria
-------------------

A child was diagnosed as VA normal (VAN) if his/her serum retinol concentration was ≥0.7 µM or as VA deficient (VAD) if his/her serum retinol concentration was \<0.7 µM. In addition, serum Zn\<10.7 µM was defined as Zn deficiency. The diagnostic criteria of anaemia were as follows: Hb\<90 g/L for children 1--4 months old, \<100 g/L for children 4--6 months old, \<110 g/L for children 6 months old to 6 years old and \<120 g/L for children 6 years old to 14 years old. Albumin (Alb) levels≥35 g/L were defined as Alb normal, and Alb levels\<35 g/L were defined as hypoalbuminemia. The normal value of serum iron is 10.7--34.0 µM. If a child's body weight was less than the mean minus the SD of the reference group (same age, same gender), he/she was considered a low body weight patient.

The evaluation criteria of the efficacy of persistent diarrhea treatment were as follows: i) significantly effective treatment: stool traits and frequency returned to normal, and systemic symptoms resolved; ii) effective treatment: stool traits and frequency and systemic symptoms clearly improved; and iii) ineffective treatment: stool traits and systemic symptoms exhibited no improvement or worsened.^([@B7])^

The assessment of intestinal microbiota dysbiosis was based on the *Fecal smear atlas for intestinal microbiota* as follows: i) normal: the proportion of normal microbes/total bacterial count and the proportions of different bacterial types were normal, and the proportion of bacilli/cocci was 3:1 or higher; ii) degree I dysbiosis: the total bacterial count was at or slightly below the lower end of the normal range, the level of Gram^+^ bacilli was low-normal, the level of Gram-- cocci was normal-high, and the proportion of bacilli/cocci was typically 1:1--2:1; iii) degree II dysbiosis: the total bacterial count was clearly reduced or exhibited no apparent change, the level of Gram^+^ bacilli was significantly decreased, the proportion of Gram^−^ cocci was clearly increased and reached as high as 90%, resulting in a reversed proportion of bacilli/cocci, and yeast species or Clostridium species were apparently increased; and iv) degree IV dysbiosis: the total bacterial count was significantly reduced and the composition of the original faecal microbiota was significantly altered with one predominant bacterial or fungal species.^([@B8])^

Statistical methods
-------------------

IBM SPSS Statistics 21.0 (International Business Machines Corporation, Newyork, NY) was used for statistical analyses. Measurement data were expressed as mean ± SD. Inter-group comparisons were made using the *t* test, ANOVA or Kruskal-Wallis Test. Count data were examined via R × C χ^2^ test. Linear correlation analysis was performed between different variables. A value of *p*\<0.05 was considered statistically significant.

Results
=======

General information
-------------------

A total of 160 paediatric patients with persistent diarrhea were examined in this study. Thirty-three children were lost to follow-up due to a change in the guardian's contact number or relocation for work, yielding a follow-up loss rate of 20.6% (Fig. [1](#F1){ref-type="fig"}). The remaining 127 children with persistent diarrhea and their families completed the entire trial, which included 81 males and 46 females (M:F = 1.76:1). The average age of the 127 children was 8.43 ± 7.45 months old. As shown in Table [1](#T1){ref-type="table"}, the sample included 113 children less than 1 years old, representing 89% of the total patient group (31 subjects less than 3 months old, 37 subjects 4--6 months old and 45 subjects 7--12 months old) as well as 8 children 1--3 years old and 6 children older than 3 years old.

Causes of diarrhea
------------------

The 127 paediatric patients with persistent diarrhea were clinically diagnosed as the following: 53 cases (42%) of a food allergic gastrointestinal disease (FAG), 22 children with secondary lactose intolerance (17%), 19 children with antibiotic-associated diarrhea (AAD) (15%), 6 children with an enteric infection (5%) and 15 cases with unknown causes (11%). Additionally, the other patients had a primary immunodeficiency disease, Bartter syndrome, renal tubule acidosis (RTA), primary enteric lymphangiectasis, Ulcerative colitis, graft versus host disease (GVHD), congenital adrenal cortical dysfunction, etc.

Furthermore, the faeces analysis of the pathological bacteria showed that among the 15 cases of FAG with infection, 9 cases suffered from *Rotavirus* enteritis, 3 cases were infected by *Escherichia coli*, and in the other 3 cases, the exact pathological bacteria were not identified. We cultured the stool of 6 children with only an enteric infection and found 2 cases of *Salmonella typhimurium*, one case with *Salmonella paratyphi C*, 2 cases with *Escherichia coli* and 1 case with a *Pseudomonas aeruginosa* infection.

Serum biochemical test
----------------------

Among the 127 children with persistent diarrhea, there were 39 subjects with low body weight, representing 30.71% of the total patient sample; the incidence of low body weight was significantly higher in our patient population than China's national average in 2002 (*p*\<0.05).^([@B9],[@B10])^ The average Hb of the sample was 108.52 ± 15.27 g/L, including 41 cases of anaemia (32.28%); the incidence of anaemia was also significantly higher than the national average (*p*\<0.05).^([@B11])^ The average albumin level was 32.37 ± 5.42 g/L, and there were 76 patients with low albumin levels (59.84%). The average VA level was 0.75 ± 0.32 µM, and there were 104 cases of VA deficiency (81.89%), which was significantly higher than the national average (*p*\<0.05);^([@B12])^ however, no cases exhibited the classical symptom of VAD. The average serum Zn level was 12.99 ± 3.35 µM, which was markedly lower than the national average (*p*\<0.05).^([@B13])^ There were 21 cases of serum Zn deficiency (16.54%). The average serum iron level was 13.51 ± 6.36 µM, and there were 38 cases with below normal levels of serum iron (29.92%) (Table [1](#T1){ref-type="table"}).

Faecal microbiota analysis
--------------------------

The faecal smear examination for the 127 children with persistent diarrhea revealed that 120 subjects (94.49%) exhibited various levels of microbiota dysbiosis. In addition, 78.74% (100/127) of the children exhibited both VA deficiency and dysbiosis. Spearman correlation analysis revealed that the VA nutritional level was correlated with a microbiota imbalance (correlation coefficient 0.212, *p*\<0.05). Based on the differential VA nutritional levels, we divided the 127 subjects into two groups: VAN and VAD. The faecal smear results of these two groups are presented in Table [2](#T2){ref-type="table"}. The 23 children in the VAN group exhibited a dysbiosis rate of 86.96% (20/23), and the majority of cases were degrees I and II dysbiosis (30.4% and 47.8%). In comparison, the dysbiosis rate in the VAD group reached 96.15% and included mostly degree II dysbiosis (74.04%). Degrees II and III dysbiosis were grouped together as medium-severe microbiota imbalance; thus, there were 84 children (80.77%) in the VAD group, and the incidence of microbiota imbalance was significantly higher than that of the VAN group (56.50%). The differences between the two groups were statistically significant (χ^2^ = 6.14, *p*\<0.01).

Analysis of random grouping
---------------------------

The 127 children with persistent diarrhea were randomly divided into four groups to perform the study. There were 33, 31, 30 and 33 children in groups A--D, respectively, and the M/F ratios and mean ages are presented in Table [3](#T3){ref-type="table"}. Statistical analysis revealed that there were no significant differences with respect to gender and age among the individual groups (*p*\>0.05).

The average body weight, haemoglobin level, albumin level, serum VA level and Zn and Fe levels of the four groups before the interventions are summarised in Table [4](#T4){ref-type="table"}. Our analysis indicated that prior to the intervention, the nutritional status, serum VA level, serum Zn and Fe levels did not differ among the four groups (*p*\>0.05), which laid the basis for a subsequent study on auxiliary treatment using VA and Zn.

Analyses of post-intervention results
-------------------------------------

### Post-intervention changes in VA, Hb and serum iron levels.

Table [5](#T5){ref-type="table"} presents VA levels of the patients with persistent diarrhea before and after the intervention. After the intervention, groups A and C exhibited increases of 0.24 ± 0.10 µM and 0.28 ± 0.09 µM in the patients' VA levels, respectively. Chi-Square analysis revealed that the VA levels differed significantly from that of the groups B and D (*p*\<0.05). There was no significant difference between group A (VA supplementation) and group C (VA + Zn supplementation), although the VA elevation in group C was more pronounced. In addition, the Hb and VA levels in the four groups before and after treatment exhibited similar trends (Table [6](#T6){ref-type="table"}). After 14 days of intervention, the Hb level in all of the groups improved to varying degrees, with groups A and C exhibiting the most significant improvements (*p*\<0.05). The aforementioned results indicate that VA or VA + Zn supplementation, particularly the latter, can improve VA levels and ameliorate anaemia in paediatric patients with persistent diarrhea.

The changes of serum iron following intervention are shown in Table [7](#T7){ref-type="table"}. After the intervention, groups A and C displayed decreases of 1.11 ± 1.14 µM and 0.30 ± 0.88 µM in the serum iron level, respectively, whereas groups B and D exhibited increases of 1.57 ± 0.69 µM and 1.19 ± 0.53 µM, respectively. There were significant differences in the changes in the serum iron level following intervention among the four groups, except between groups B and D.

### Influences of different interventions on the treatment outcomes for persistent diarrhea.

The four groups with persistent diarrhea were subject to routine treatment in conjunction with VA and/or Zn supplementation. After 5 days, the treatment efficacy was compared among the 127 children (Table [8](#T8){ref-type="table"}). The total efficacy rates in the four groups were 63.64%, 90.32%, 93.33% and 54.55%, respectively, with groups B and C exhibiting the best outcomes, followed by group A. The χ^2^ test revealed that the differences between groups B and C and group D were significant (*p*\<0.05), as were the differences between group A and groups B and C (*p*\<0.05). However, there was no apparent difference between groups B and C (*p*\>0.05). These results indicate that short-term Zn and VA + Zn supplementation can improve, to different degrees, the treatment outcomes of children with persistent diarrhea.

Table [9](#T9){ref-type="table"} summarises the treatment outcomes of the patients with persistent diarrhea. Twenty four, 26 and 25 patients in groups A, B and C, respectively, exhibited improvements in their persistent diarrhea, representing superior efficacy to the improvement of the 14 patients in group D (*p*\<0.05). The total effectiveness rates of groups A, B, and C were 93.94%, 96.77% and 96.67%, respectively, and there were no significant differences among the three groups. In contrast, the three groups exhibited superior efficacy relative to group D (72.73%), as revealed by the χ^2^ test (*p*\<0.05). These results indicate that when treating paediatric patients with persistent diarrhea using conventional approaches, simultaneous supplementation with VA, Zn or VA + Zn can improve the therapeutic outcomes.

Discussion
==========

Persistent diarrhea is a common paediatric disease among Chinese children, of which, the aetiologies are complex and numerous. In the present study, the top three causes of persistent diarrhea were FAG (42%), secondary lactose intolerance (17%) and AAD (15%) in the 127 paediatric patients. However, enteric bacterial infection was only present in 5% of the 127 subjects with persistent diarrhea, where the primary pathogenic bacteria were *Escherichia coli* and *Salmonella*. In addition, there were 15 cases (11%) with unclear causes of persistent diarrhea.

Persistent diarrhea is also a frequent cause of childhood malnutrition and growth retardation, which may be life-threatening. VA deficiency is ubiquitously present in developing countries and is associated with increased incidences of pneumonia and diarrhea. As such, enhanced VA supplementation has significantly decreased the hospitalisation rate of children with chronic diarrhea in Bangladeshi.^([@B14])^ Nevertheless, it remains unclear whether VA can assist treatment for persistent diarrhea.

Among the 127 children with persistent diarrhea examined in this study, there were 39 cases of low body weight and 41 cases of anaemia, yielding incidence rates of 30.71% and 32.28%, respectively, which were both significantly higher than the national averages.^([@B9]--[@B11])^ In addition, 59.84% of the children exhibited various levels of hypoalbuminemia. Our results also revealed that the average serum VA level in the study sample was lower than that of healthy children under 5 years old in China (1.06 ± 0.33 µM),^([@B12])^ which is consistent with the results of Abrol.^([@B15])^ These findings indicated that low VA levels are commonly present in children with persistent diarrhea, possibly because protracted diarrhea leads to the malabsorption of nutrients that, in turn, results in anaemia, malnutrition, poor immune function and growth and development disorders.

In this study, we randomly divided the 127 subjects with persistent diarrhea into four groups, which did not differ with respect to age, gender, serum VA level or serum Zn and Fe level before the interventions. The children were provided with auxiliary treatment with VA (group A), Zn (group B) or VA + Zn (group C), with the Zn treatment serving as the positive control for auxiliary treatment and no intervention serving as the negative control (group D).^([@B16])^ Supplementation with VA and VA + Zn increased the serum VA levels and ameliorated anaemia. These results are consistent with our previous studies.^([@B17]--[@B19])^ Among these treatments, VA + Zn supplementation exhibited the most pronounced improvement effects on childhood anaemia, indicating that concurrent intervention with multiple micronutrients may result in synergistic modulation.^([@B16],[@B20]--[@B22])^ Single Zn supplementation did not improve the serum VA level or anaemic status of the patients with persistent diarrhea; there were no significant differences between the Zn group and the control group. This finding indicates that Zn treatment cannot improve the VA nutritional level or anaemia of children with persistent diarrhea.

As is known, serum iron (SI) primarily reflects the stock status of liver iron. An increasing SI level results in an increase in the iron reserve, whereas a decreasing SI level indicates a decrease in the iron reserve. Either iron deficiency or increasing iron mobilisation can decrease the SI level. A study has revealed that VA improves the storage and utilisation of iron but has only a slight effect on the absorption of iron.^([@B23])^ Consistent with Chen's report, we also found that VA supplementation decreased the SI level and increased the Hb level of the paediatric patients with persistent diarrhea, indicating that VA could promote Hb synthesis by increasing iron mobilisation.^([@B24])^ Consequently, the decrease in SI level was associated with mobilisation of liver reserve iron and not an iron deficiency. Zn, as an important trace element in human, widely exists in the body and is crucial in biological functions. Our study revealed that serum iron level increased following single Zn administration; however, there was no significant difference compared with the non-intervention group. Although recent studies have found that zinc supplementation decreases the serum iron concentration in healthy schoolchildren and non-anaemic women, short-term zinc intervention cannot significantly change the serum iron concentration.^([@B20],[@B21],[@B25])^ It was intriguing that the concurrent VA + Zn supplementation slighly decreased the SI level of peadiatric patients. The reason was speculated to be a double effects in which VA promoted iron mobilisation but did not affect iron absorption; VA + Zn had the best treatment efficacy that increased serum iron level in a short period of time.^([@B19])^ Determining the exact mechanism requires further study.

A comparison of the treatment efficacy for persistent diarrhea performed after 5 days of treatment revealed that the total effectiveness rates of the Zn and VA + Zn supplementation were both significantly higher than those of the control group and single VA supplementation; in addition, there was no significant difference in treatment efficacy between the control group and single VA group or between the concurrent VA + Zn group and the single Zn group. Nonetheless, as the treatment time extended, the VA supplementation resulted in a superior outcome relative to the control group, whereas the other three intervention treatments exhibited no significant differences, which is consistent with a study by Walser.^([@B22])^

VA is increasingly recognised to counteract infection and promote epithelial barrier function and intestinal mucosal immunity. Studies have indicated that retinoic acid (RA), an important intermediate metabolite of VA, can induce T and B cells to express homing receptors α4β7 and CCR9, which thereby regulates mucosal immune responses.^([@B26],[@B27])^ Our preliminary experiments also revealed that VA deficiency during pregnancy or in early life can decrease intestinal IgA secretion and influences the numbers of B cells, dendritic cells and T cells in gut-associated lymphoid tissues.^([@B28])^ Meta-analyses indicate that Zn supplementation can decrease the duration and severity of persistent diarrhea.^([@B29],[@B30])^ Likewise, Rahman reported that concurrent VA + Zn supplementation can significantly reduce the incidence of persistent diarrhea.^([@B16])^ Therefore, we investigated VA supplementation and used a Zn auxiliary treatment as a positive control, thereby generating three interventional approaches. A comparison revealed that Zn significantly enhanced the treatment efficiency in patients with persistent diarrhea, whereas VA supplementation promoted treatment efficacy, enhanced the VA level and improved the anaemic status of the children. These results therefore indicate that concurrent supplementation of VA and Zn is the optimal auxiliary treatment for persistent diarrhea and can break the vicious cycle of "diarrhea-malnutrition-diarrhea" and protect children from growth retardation.

Gut microbiota imbalances damage the intestinal barrier and may contribute to diarrhea-predominant irritable bowel syndrome, inflammatory bowel disease and necrotising enterocolitis.^([@B31])^ Patients with diarrhea-predominant irritable bowel syndrome exhibit a reduced number of beneficial microbiota, elevated numbers of harmful microorganisms and decreased intestinal microbial diversity.^([@B32],[@B33])^ Furthermore, gut flora imbalances and damage to the intestinal barrier are crucial pathogenic factors.^([@B34])^ This study also revealed that subjects with dysbiosis represented 94.49% of the persistent diarrhea cohort, suggesting a close association between persistent diarrhea and gut dysbiosis. Jejunum, ileum and colon tissues deficient in VA exhibit reductions in *Lactobacillus* spp. of 62%, 82% and 86%, respectively, as well as a striking elevation of *Escherichia coli* strains.^([@B35])^ Our study demonstrated that subjects with simultaneous VAD and dysbiosis accounted for 78.74% of the study cohort and that the proportion of severe dysbiosis subjects in the VAD group was markedly higher than that of the VAN group, suggesting an intricate relationship between VA nutrition status and dysbiosis in children with persistent diarrhea. A future focus of our group will be to elucidate whether VA auxiliary treatment can ameliorate gut dysbiosis in children with persistent diarrhea and how the VA nutritional level regulates intestinal microbiota at the molecular level.

In summary, our study reveals that children with persistent diarrhea exhibit a plethora of prominent nutrition problems, including low body weight, anaemia, VA deficiency and hypoproteinemia. Our data also support a close association between VA nutrition level and faecal dysbiosis in paediatric patients. In addition, single VA supplementation, single Zn supplementation, and concurrent VA + Zn supplementation can significantly boost the therapeutic efficacy of treatment for persistent diarrhea and decrease the disease duration. However, concurrent VA + Zn supplementation generates the best outcome by increasing the overall treatment effectiveness rate for persistent diarrhea as well as by improving the nutritional status of paediatric patients.

This work was supported by National Nature Science Foundation of China (grant number 81070286, 81470799) and Science & Technology Project of Yuzhong District of Chongqing (2012). We would like to thank all the paediatric patients enrolled in this study and their guardians.

AAD

:   antibiotic-associated diarrhea

Alb

:   albumin

FAG

:   food allergic gastrointestinal disease

SI

:   serum iron

VA

:   vitamin A

VAD

:   vitamin A deficiency

VAN

:   vitamin A normal

Conflict of Interest
====================

No potential conflicts of interest were disclosed.

![Flow chart.](jcbn15-68f01){#F1}

###### 

Analysis of 127 children with persistent diarrhea

                                         Number (*n*)
  ------------------ ------------------- --------------
  Gender             Male                81
                     Female              46
                                         
  Age                ≤3 months           31
                     4--6 months         37
                     7--12 months        45
                     1--3 years          8
                     ≥3 years            6
                                         
  Weight-for-age     normal              88
                     low body weight     39
                                         
  Hemoglobin (Hb)    normal              86
                     anemia              41
                                         
  Albumin level      normal              51
                     Hypoproteinemia     76
                                         
  Vitamin A level    normal              23
                     VA deficiency       104
                                         
  Zinc level         normal              106
                     Zinc insufficient   21
                                         
  Serum iron level   normal              89
                     iron insufficient   38

###### 

Analysis of intestinal flora smear between the VAN and VAD groups

  Group   Normal *n* (%)   Dysbacteriosis   Serious dysbacteriosis a = II + III (%)                
  ------- ---------------- ---------------- ----------------------------------------- ------------ --------------------
  VAN     3 (13.0)         7.0 (30.40)      11.0 (47.80)                              2.0 (8.70)   13.0 (56.50)**\***
  VAD     4 (3.85)         16.0 (15.38)     77.0 (74.03)                              7.0 (6.73)   84.0 (80.77)

**\***χ^2^ = 6.14, vs the VAD group, *p*\<0.05.

###### 

The gender composition and average age among the four groups^†^

  Group   Number   Gender   Age (months)   
  ------- -------- -------- -------------- -------------
  A       33       21       12             8.72 ± 7.29
  B       31       20       11             8.50 ± 7.38
  C       30       18       12             8.21 ± 7.01
  D       33       22       11             8.86 ± 8.34
  Total   127      81       46             8.43 ± 7.45

Results are expressed as mean ± SD. ^†^There are no significant differences among the groups, *p*\>0.05.

###### 

Comparison of nutritional status between groups^†^

  Group   Number   Wt (kg)       Hb (g/L)         Alb (g/L)      Zn (mM)        Fe (µM)        VA (mM)
  ------- -------- ------------- ---------------- -------------- -------------- -------------- -------------
  A       33       8.50 ± 1.94   109.12 ± 11.23   33.0 ± 3.89    12.64 ± 3.30   13.13 ± 5.05   0.73 ± 0.30
  B       31       7.22 ± 1.95   112.52 ± 11.85   34.14 ± 4.0    13.94 ± 3.91   13.13 ± 7.97   0.79 ± 0.33
  C       30       7.26 ± 1.76   111.86 ± 15.17   33.09 ± 5.29   12.83 ± 2.95   13.12 ± 6.25   0.73 ± 0.42
  D       33       7.06 ± 2.53   101.32 ± 19.42   29.58 ± 6.92   12.59 ± 3.86   14.59 ± 6.10   0.74 ± 0.26

Results are expressed as mean ± SD. ^†^There are no significant differences among the groups, *p*\>0.05.

###### 

The serum VA levels among the four groups after 14 days intervention

  Group   Number   Mean of VA level (mM)   Mean of VA level after 14 days intervention (mM)   Mean of average increase (mM)
  ------- -------- ----------------------- -------------------------------------------------- -------------------------------
  A       33       0.73 ± 0.30             0.98 ± 0.40                                        0.24 ± 0.10**\***
  B       31       0.79 ± 0.33             0.85 ± 0.38                                        0.06 ± 0.05
  C       30       0.73 ± 0.42             1.01 ± 0.51                                        0.28 ± 0.09^†^
  D       33       0.74 ± 0.26             0.79 ± 0.30                                        0.05 ± 0.03

Results are expressed as mean ± SD. **\***Compared with group B, *p*\<0.05. ^†^Compared with group D, *p*\<0.01.

###### 

The Hb levels among the four groups after 14 days intervention

  Group   Number   Mean of Hb level (g/L)   Mean of Hb level after 14 days intervention (g/L)   Mean of average increase (g/L)
  ------- -------- ------------------------ --------------------------------------------------- --------------------------------
  A       33       109.12 ± 11.23           114.22 ± 13.47                                      5.11 ± 2.23**\***
  B       31       112.52 ± 11.85           114.52 ± 13.55                                      2.43 ± 1.70
  C       30       111.86 ± 15.17           119.28 ± 19.85                                      7.43 ± 4.67^†^
  D       33       101.32 ± 19.42           103.65 ± 20.52                                      2.23 ± 1.09

Results are expressed as mean ± SD. **\***Compared with group B, *p*\<0.05. ^†^Compared with group D, *p*\<0.01.

###### 

The changes of the serum iron before and after intervention

  Group   Number   Mean of Fe level (µM)   Mean of Fe level after 14 days intervention (µM)   Mean of average increase (µM)
  ------- -------- ----------------------- -------------------------------------------------- -------------------------------
  A       33       13.13 ± 5.05            12.02 ± 4.33                                       --1.11 ± 1.14**\***^,†,‡^
  B       31       13.13 ± 7.97            14.70 ± 7.86                                       1.57 ± 0.69^§,\|\|^
  C       30       13.12 ± 6.25            12.82 ± 5.85                                       --0.30 ± 0.88^¶^
  D       33       14.59 ± 6.10            15.78 ± 6.10                                       1.19 ± 0.53

Results are expressed as mean ± SD. **\***Compared with B group, *p*\<0.001. ^†^Compared with C group, *p*\<0.05. ^‡^Compared with D group, *p*\<0.001. ^§^Compared with C group, *p*\<0.001. ^\|\|^Compared with D group, *p\>*0.05. ^¶^Compared with D group, *p*\<0.001.

###### 

Comparison of the curative effect among the four groups after 5 days intervention

  Group   Number   The curative effect   The total effective**\*** *n* (%)                  
  ------- -------- --------------------- ----------------------------------- -------------- -------------------
  A       33       6.0 (18.18)           15.0 (45.45)                        12.0 (36.36)   21.0 (63.64)^†,‡^
  B       31       8.0 (25.81)           20.0 (64.52)                        3.0 (9.68)     28.0 (90.32)^§^
  C       30       7.0 (23.33)           21.0 (70.0)                         2.0 (6.67)     28.0 (93.33)^§^
  D       33       4.0 (12.12)           14.0 (42.42)                        15.0 (45.45)   18.0 (54.55)

**\***The total effective = Excellence + Effective. ^†^Compared with B group, *p*\<0.05. ^‡^Compared with C group, *p*\<0.01. ^§^Compared with D group, *p*\<0.01.

###### 

Comparison of the curative effect among the four groups after 14 days intervention

  Group   Number   The curative effect   The total effective**\*** *n* (%)                
  ------- -------- --------------------- ----------------------------------- ------------ -----------------
  A       33       24.0 (72.73)^†^       7.0 (21.21)                         2.0 (0.06)   31.0 (93.94)^§^
  B       31       26.0 (83.70)^‡^       4.0 (12.90)                         1.0 (0.03)   30.0 (96.77)^§^
  C       30       25.0 (8.33)^‡^        4.0 (0.13)                          1.0 (0.03)   29.0 (96.67)^§^
  D       33       14.0 (0.48)           10.0 (0.33)                         9.0 (0.18)   24.0 (72.73)

**\***The total effective = Excellence + Effective. ^†^Compared with D group, *p*\<0.05. ^‡^Compared with D group, *p*\<0.01. ^§^Compared with D group, *p*\<0.05.
